SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics (NASDAQ: CYTX) received an order for a StemSource® Cell Bank from Cosmetic Surgery Seishin in Japan. The Cell Bank includes a StemSource® processing system along with all other equipment, software, database, and protocols required to cryopreserve patients’ own adipose-derived regenerative cells when the cells are younger and more viable.
